Skip to content
Screener

Altimmune ALT Q4 2025 Annual earnings

Reported March 5, 2026 · Before market open

Revenue$26.0KBeat by $25.4K
EPS-$0.27Miss by $0.02
Revenue estimate$556.0
EPS estimate-$0.25

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$1.8K
EPS estimate-$0.14

Financials

Q4 2025

Income statement

See full
Revenue$26.0K+420%
Operating income-$28.9M-16.2%
Net income-$27.4M-18.0%
EPS (diluted)-$0.26+21.2%

Balance sheet

See full
Cash & equivalents$43.8M+18.5%
Total debt$35.7M+2,023%
Total equity$224.9M+82.1%
Total assets$279.9M+101%

Cash flow

See full
Operating cash flow-$19.4M-6.5%
CapEx$1.0K—
Free cash flow-$19.4M—

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$376.68M-26.5%
Enterprise value$368.56M-22.8%
P/S9,187.2×-16,453×

Profitability

See full
Operating margin-230,461%-82,087pp
Net margin-214,861%-76,057pp

Returns & leverage

See full
Return on equity-50.6%-6.8pp
Debt / equity0.2×+0.1×
Current ratio18.5×+5.4×

FAQ

When did Altimmune report Q4 2025 earnings?
Altimmune (ALT) reported Q4 2025 earnings on March 5, 2026 before market open.
What were Altimmune's Q4 2025 revenue and EPS?
Altimmune reported revenue of $26.0K and eps of $-0.27 for Q4 2025.
Did Altimmune beat estimates in Q4 2025?
Revenue beat the consensus estimate of $556.0 by $25.4K. EPS missed the consensus estimate of $-0.25 by $0.02.
How did Altimmune's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 420.0% from $5.0K a year earlier and eps grew 18.2% from $-0.33.
Where can I find Altimmune's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001326190-26-000013) and the 10-K periodic report (0001326190-26-000018) directly on SEC EDGAR. The filing index links above go to sec.gov.